Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

180 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-01

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The association of novel inflammatory biomarkers with cardiovascular diseases is still obscure. The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission. Methods: We enrolled a total of 120 patients with HF, asymptomatic CAD and 60 healthy controls (HC) without cardiovascular diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Empagliflozin on Patients With Preserved Heart Failure

NCT07112274

Heart Failure

COMPLETED NA

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

NCT06065280

Heart Failure Reduced Ejection Fraction Heart Failure

COMPLETED NA

Dapagliflozin in the Treatment of Heart Failure

NCT05727423

Heart Failure

ACTIVE_NOT_RECRUITING

The Effect of Inflammation in Heart Failure

NCT05330013

Myocardial Dysfunction Heart Failure Inflammation

WITHDRAWN PHASE2

Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus

NCT06632561

Heart Failure With Reduced Ejection Fraction

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission in patients on empagliflozin 10 mg once daily for 6 months before the beginning of the study.
* We enrolled a total of 60 patients with HF, 60 asymptomatic CAD patients and 60 healthy controls (HC) without cardiovascular diseases.

Group I: 60 Healthy Subjects. Group II: 60 Patients with Stable Angina (asymptomatic CAD). Group III: 60 Patients with Heart Failure.

* Clinical parameters, glycemic and lipid profile, vaspin, visfatin, high-sensitivity C-reactive protein, sortilin, homocysteine, troponin I, fetuin A and lipoprotein A levels were assayed.
* Patients will be followed up to assess all-cause 30- and -90 day of hospital readmission.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stable Angina Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group I

60 Healthy Subjects.

Group I Healthy

Intervention Type OTHER

Healthy Subjects

Group II

60 Patients with Stable Angina on empagliflozin 10 mg once daily for 6 months before the beginning of the study.

CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study

Intervention Type DRUG

Group II: Stable Angina Patients

Group III

60 Patients with Heart Failure on empagliflozin 10 mg once daily for 6 months before the beginning of the study.

HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study

Intervention Type DRUG

Group III: Heart Failure Patients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Group I Healthy

Healthy Subjects

Intervention Type OTHER

CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study

Group II: Stable Angina Patients

Intervention Type DRUG

HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study

Group III: Heart Failure Patients

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Empa- CAD Empa-HF

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Either sex, aged 18 years or older.
* new-onset AHF or acute decompensation of chronic HF,
* CAD (including previous myocardial infarction, previous percutaneous or surgical coronary revascularization, or angiographic evidence that one or more major coronary arteries had narrowed by 50% or more).
* On empagliflozin 10 mg once daily for 6 months before the beginning of the study.

Exclusion Criteria

* severe liver/
* kidney dysfunction;
* severe systemic disease (such as the diseases of respiratory system/ digestive system/ nervous system etc.);
* malignant tumor;
* acute/ chronic infectious diseases;
* autoimmune disease or connective tissue disease;
* major trauma or surgical operation over the past three months.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No